• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

疑似耐多药结核病患者的筛查结果:菲律宾的经验教训。

Screening outcomes from patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines.

机构信息

Tropical Disease Foundation, Makati City, Philippines.

出版信息

Int J Tuberc Lung Dis. 2012 Oct;16(10):1326-30. doi: 10.5588/ijtld.12.0038. Epub 2012 Aug 3.

DOI:10.5588/ijtld.12.0038
PMID:22863522
Abstract

SETTING

The high prevalence of multidrug-resistant tuberculosis (MDR-TB) in the Philippines is a challenge for the National TB Programme.

OBJECTIVE

To assess patterns of drug resistance and screening outcomes among MDR-TB suspects evaluated from 2003 to 2008 at DOTS-Plus clinics in the Philippines.

METHODS

Descriptive study of 4897 consecutive patients with suspected MDR-TB.

RESULTS

The median time from the first visit until a diagnosis of drug-resistant TB was 132 days (IQR 110-166 days). Among patients screened for MDR-TB, the most frequent resistance pattern among those previously treated in DOTS facilities was resistance to isoniazid (INH) and rifampicin (RMP). Resistance to INH+RMP plus fluoroquinolones was the most common pattern among those who had failed Category II treatment and patients treated by non-DOTS facilities. Among patients with MDR-TB, 57% ultimately received appropriate treatment with second-line drugs. The remaining 43% were lost to follow-up (25%), died (14%) or refused treatment (4%).

CONCLUSION

Resistance to INH+RMP is the most frequent resistance pattern among patients referred from DOTS clinics in the Philippines for suspected MDR-TB. Initial use of standard regimens based on national survey data and quick uptake of new rapid molecular resistance tests may be useful to reduce diagnostic delays and expedite treatment for drug-resistant TB.

摘要

背景

菲律宾耐多药结核病(MDR-TB)的高患病率给国家结核病规划带来了挑战。

目的

评估 2003 年至 2008 年期间在菲律宾 DOTS-Plus 诊所评估的疑似耐多药结核病患者的耐药模式和筛查结果。

方法

对 4897 例连续疑似耐多药结核病患者进行描述性研究。

结果

从首次就诊到确诊耐药性结核病的中位时间为 132 天(IQR 110-166 天)。在筛查耐多药结核病的患者中,在 DOTS 设施中接受过治疗的患者中最常见的耐药模式是异烟肼(INH)和利福平(RMP)耐药。在失败的 II 类治疗和非 DOTS 设施治疗的患者中,INH+RMP 加氟喹诺酮类耐药最常见。在耐多药结核病患者中,57%最终接受了二线药物的适当治疗。其余 43%失访(25%)、死亡(14%)或拒绝治疗(4%)。

结论

INH+RMP 耐药是菲律宾 DOTS 诊所转诊的疑似耐多药结核病患者中最常见的耐药模式。根据国家调查数据初始使用标准方案和快速采用新的快速分子耐药检测可能有助于减少诊断延误并加快耐药结核病的治疗。

相似文献

1
Screening outcomes from patients with suspected multidrug-resistant tuberculosis: lessons learned in the Philippines.疑似耐多药结核病患者的筛查结果:菲律宾的经验教训。
Int J Tuberc Lung Dis. 2012 Oct;16(10):1326-30. doi: 10.5588/ijtld.12.0038. Epub 2012 Aug 3.
2
Multidrug-resistant tuberculosis among previously treated patients in the Philippines.菲律宾曾接受治疗的患者中的耐多药结核病。
Int J Tuberc Lung Dis. 2011 May;15(5):652-6. doi: 10.5588/ijtld.10.0400.
3
Tuberculosis drug resistance and treatment outcomes under DOTS settings in large cities in the Philippines.菲律宾大城市直接督导下的短程化疗(DOTS)模式下的结核病耐药性及治疗结果
Int J Tuberc Lung Dis. 2006 Mar;10(3):283-9.
4
Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment.1986 - 1999年香港实施直接督导治疗后结核分枝杆菌耐药性监测
Int J Tuberc Lung Dis. 2001 Sep;5(9):815-23.
5
Nature of drug resistance and predictors of multidrug-resistant tuberculosis among patients seen at the Philippine General Hospital, Manila, Philippines.菲律宾马尼拉市菲律宾总医院收治患者的耐药性质及耐多药结核病的预测因素
Int J Tuberc Lung Dis. 1997 Feb;1(1):59-63.
6
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].[耐异烟肼或耐利福平结核病的特征及治疗结果]
Kekkaku. 2003 Oct;78(10):611-7.
7
First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia.埃塞俄比亚西北部的一线和二线抗结核药物耐药性。
Int J Tuberc Lung Dis. 2012 Jun;16(6):805-11. doi: 10.5588/ijtld.11.0522. Epub 2012 Feb 29.
8
Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.修订后的 II 类方案可作为 I 类方案失败和不规则治疗病例再治疗的替代策略。
Am J Ther. 2011 Sep;18(5):343-9. doi: 10.1097/MJT.0b013e3181dd60ec.
9
Surveillance of drug-resistant tuberculosis in the state of Gujarat, India.印度古吉拉特邦耐药结核病监测
Int J Tuberc Lung Dis. 2009 Sep;13(9):1154-60.
10
The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.南非开普敦儿童中耐药结核病的流行演变。
Int J Tuberc Lung Dis. 2012 Jul;16(7):928-33. doi: 10.5588/ijtld.11.0679. Epub 2012 May 8.

引用本文的文献

1
Time to treatment for rifampicin-resistant tuberculosis: systematic review and meta-analysis.利福平耐药结核病的治疗时间:系统评价和荟萃分析。
Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1173-1180. doi: 10.5588/ijtld.17.0230.
2
Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in Brazil.巴西五个参考中心疑似耐多药结核病患者的治疗结果。
BMC Infect Dis. 2017 Aug 15;17(1):571. doi: 10.1186/s12879-017-2669-1.